These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9778756)

  • 1. Respiratory syncytial virus infection in older persons.
    Falsey AR
    Vaccine; 1998 Nov; 16(18):1775-8. PubMed ID: 9778756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Bunting D; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1996 Jan; 15(1):23-31. PubMed ID: 8684872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection.
    Piedra PA; Glezen WP; Kasel JA; Welliver RC; Jewel AM; Rayford Y; Hogerman DA; Hildreth SW; Paradiso PR
    Vaccine; 1995 Aug; 13(12):1095-101. PubMed ID: 7491817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.
    Tristram DA; Welliver RC; Hogerman DA; Hildreth SW; Paradiso P
    Vaccine; 1994 May; 12(6):551-6. PubMed ID: 8036830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults.
    Falsey AR; Walsh EE
    J Infect Dis; 1998 Feb; 177(2):463-6. PubMed ID: 9466538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
    Groothuis JR; King SJ; Hogerman DA; Paradiso PR; Simoes EA
    J Infect Dis; 1998 Feb; 177(2):467-9. PubMed ID: 9466539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis.
    Piedra PA; Grace S; Jewell A; Spinelli S; Hogerman DA; Malinoski F; Hiatt PW
    Pediatr Infect Dis J; 1998 Mar; 17(3):217-24. PubMed ID: 9535249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly.
    Falsey AR; Walsh EE
    Vaccine; 1997 Jul; 15(10):1130-2. PubMed ID: 9269057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.
    Gonzalez IM; Karron RA; Eichelberger M; Walsh EE; Delagarza VW; Bennett R; Chanock RM; Murphy BR; Clements-Mann ML; Falsey AR
    Vaccine; 2000 Mar; 18(17):1763-72. PubMed ID: 10699324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus.
    Bastien N; Trudel M; Simard C
    Virology; 1997 Jul; 234(1):118-22. PubMed ID: 9234952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus.
    Hancock GE; Smith JD; Heers KM
    J Infect Dis; 2000 May; 181(5):1768-71. PubMed ID: 10823781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
    Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus infection in adults.
    Falsey AR
    Semin Respir Crit Care Med; 2007 Apr; 28(2):171-81. PubMed ID: 17458771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with respiratory syncytial virus vaccines.
    Piedra PA
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.